Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2021 Mar 18;13(3):500.
doi: 10.3390/v13030500.

A Reduced Dose Whole Virion Aluminum Adjuvanted Seasonal Influenza Vaccine Is Immunogenic, Safe, and Well Tolerated in Pediatric Patients

Zoltan Vajo  1 , Gergely Balaton  2 , Peter Vajo  3 , Peter Torzsa  1
Affiliations
Clinical Trial

A Reduced Dose Whole Virion Aluminum Adjuvanted Seasonal Influenza Vaccine Is Immunogenic, Safe, and Well Tolerated in Pediatric Patients

Zoltan Vajo et al. Viruses. .

Abstract

Background: Data suggest that pediatric patients might react differently to influenza vaccination, both in terms of immunity and side effects. We have recently shown that using a whole virion vaccine with aluminum phosphate adjuvants, reduced dose vaccines containing 6 µg of viral hemagglutinin (HA) per strain are immunogenic, and well tolerated in adult and elderly patients. Here we show the results of a multicenter clinical trial of pediatric patients, using reduced doses of a new, whole virion, aluminum phosphate adjuvanted vaccine (FluArt, Budapest, Hungary).

Methods: A total of 120 healthy volunteers were included in two age groups (3-11 years, receiving 3 µg of HA per strain, and 12-18 years, receiving 6 µg of HA per strain). We used hemagglutination inhibition testing to assess immunogenicity, based on EMA and FDA licensing criteria, including post/pre-vaccination geometric mean titer ratios, seroconversion and seropositivity rates. Safety and tolerability were assessed using CHMP guidelines.

Results: All subjects entered the study and were vaccinated (ITT population). All 120 subjects attended the control visit on Day 21 (PP population). All immunogenicity licensing criteria were met in both age groups for all three vaccine virus strains. No serious adverse events were detected and the vaccine was well tolerated by both age groups.

Discussion: Using a whole virion vaccine and aluminum phosphate adjuvants, a reduction in the amount of the viral hemmaglutinin is possible while maintaining immunogenicity, safety and tolerability in pediatric and adolescent patients.

Keywords: children; immunogenicity; influenza; reactogenity; vaccine.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Poehling K.A., Edwards K.M., Weinberg G.A., Szilagyi P., Staat M.A., Iwane M.K., Bridges C.B., Grijalva C.G., Zhu Y., Bernstein D.I., et al. The Underrecognized Burden of Influenza in Young Children. N. Engl. J. Med. 2006;355:31–40. doi: 10.1056/NEJMoa054869. - DOI - PubMed
    1. Wilkins A.L., Kazmin D., Napolitani G., Clutterbuck E.A., Pulendran B., Siegrist C.-A., Pollard A.J. AS03- and MF59-Adjuvanted Influenza Vaccines in Children. Front. Immunol. 2017;8:1760. doi: 10.3389/fimmu.2017.01760. - DOI - PMC - PubMed
    1. Trogstad L., Bakken I.J., Gunnes N., Ghaderi S., Stoltenberg C., Magnus P., Håberg S.E. Narcolepsy and hypersomnia in Norwegian children and young adults following the influenza A(H1N1) 2009 pandemic. Vaccine. 2017;35:1879–1885. doi: 10.1016/j.vaccine.2017.02.053. - DOI - PubMed
    1. Grohskopf L.A., Sokolow L.Z., Broder K.R., Walter E.B., Bresee J.S., Fry A.M., Jernigan D.B. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices—United States, 2017–2018 Influenza Season. MMWR Recomm. Rep. 2017;67:1. doi: 10.15585/mmwr.rr6703a1. - DOI - PMC - PubMed
    1. Jefferson T., Rivetti A., Harnden A., Di Pietrantonj C., Demicheli V. Vaccines for preventing influenza in healthy children. Cochrane Database Syst. Rev. 2012;8:CD004879. doi: 10.1002/14651858.CD004879.pub4. - DOI - PMC - PubMed

MeSH terms